From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops. Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies. More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With some […]
Abbott
Abbott launches digital health app for neurostimulation in Canada
Abbott (NYSE:ABT) announced today that it received Health Canada licensing for its NeuroSphere Virtual Clinic, enabling it to launch the app. The Abbott Park, Illinois–based company designed the remote programming technology — the first of its kind in Canada — with compatibility with Abbott’s suite of neuromodulation technologies, offering the potential to increase access to […]
Abbott posts Street-beating Q2, raises 2022 guidance
Abbott (NYSE:ABT) shares are down today despite second-quarter results that topped the consensus forecast. The Abbott Park, Illiniois–based company posted profits of more than $2 billion, or $1.14 per share, on sales of $11.3 billion for the three months ended June 30, 2022, for a 69.7% bottom-line gain on sales growth of 10.1%. Adjusted to […]
Abbott wins breakthrough nod for deep brain stimulation for managing severe depression
Abbott (NYSE:ABT) announced today that it received FDA breakthrough device designation for its deep brain stimulation (DBS) system. The breakthrough nod allows Abbott to investigate the use of its DBS system in treatment-resistant depression (TRD), a form of major depressive disorder (MDD). Abbott Park, Illinois-based Abbott designed its DBS system as a personalized, adjustable therapy […]
Abbott Fund grants $750k to education, health equity program
Easterseals announced that it received a $750,000 grant from the Abbott Fund to pilot the Project on Education and Community Health Equity. The grant will fund the project from now through 2025, with the three-year initiative aimed at addressing systemic barriers to high-quality education and healthcare experienced by children and families in underserved communities. According […]
Another Medtronic HVAD recall is serious
A year after Medtronic ceded the LVAD market to Abbott, it has yet another Class I recall involving HeartWare Ventricular Assist Device pumps still implanted in patients. The FDA today designated a Medtronic recall involving the HVADs as Class I, the most serious level. It’s the second Class I recall designation for the HVADs this […]
Abbott presents positive data on MitraClip, TriClip heart implants
Abbott (NYSE:ABT) today announced late-breaking data supporting its MitraClip and TriClip structural heart solutions. Data for the MitraClip transcatheter edge-to-edge repair (TEER) device and the TriClip minimally invasive tricuspid heart valve repair device were presented at TVT: The Structural Heart Summit, the annual meeting from the Cardiovascular Research Foundation in Chicago. The company said in […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. The […]
Late-breaking data supports Abbott FreeStyle Libre 3 in 14-day glucose monitoring
Abbott (NYSE:ABT) announced data demonstrating the accuracy of its next-generation FreeStyle Libre 3 continuous glucose monitor (CGM). The latest version of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world at the size of just two stacked U.S. pennies — picked up FDA clearance for people with diabetes aged […]
Abbott to develop biowearable for continuous monitoring of glucose, ketone levels
Abbott (NYSE:ABT) announced today that it is developing a new biowearable for continuously monitoring both glucose and ketone levels. The all-in-one sensor has already garnered FDA breakthrough device designation and will be used in pivotal trials in 2023, with regulatory submissions to follow thereafter. Get the full story at our sister site, Drug Delivery Business News.
FDA clears Abbott’s next-gen FreeStyle Libre 3 14-day CGM
Abbott (NYSE:ABT) announced today that it received FDA clearance for its next-generation FreeStyle Libre 3 continuous glucose monitor. FDA clearance for the latest iteration of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world — covers use by people 4 years of age and older living with diabetes. […]
